Blind Trust in Supplier Certificates and Inadequate Final Testing - An Analysis of FDA Warning Letter
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
Related GMP News
28.04.2026FDA remains active in Europe - further Inspections despite MRAs
22.04.2026No Validation, No Controls, and No Suitable Rooms and Equipment - Extensive Warning Letter
25.03.2026FDA Warning Letter highlights once again: Weaknesses in the CAPA Process remain a key GMP Issue
18.03.2026FDA Issues Draft Guidance on Responding to Form 483 Observations
28.01.2026What is the Procedure for GMP Inspections (EU GMP inspections and FDA Inspections)?
21.01.2026FDA Warning Letter highlights critical Failures in Supplier and Quality Oversight